Development of 3D-iNET ORION: a novel, pre-clinical, three-dimensional in vitro cell model for modeling human metastatic neuroendocrine tumor of the pancreas.

3D cancer cell lines Neuroendocrine tumor Pancreas

Journal

Human cell
ISSN: 1749-0774
Titre abrégé: Hum Cell
Pays: Japan
ID NLM: 8912329

Informations de publication

Date de publication:
05 Aug 2024
Historique:
received: 19 01 2024
accepted: 08 07 2024
medline: 6 8 2024
pubmed: 6 8 2024
entrez: 5 8 2024
Statut: aheadofprint

Résumé

Neuroendocrine tumors (NETs) of the pancreas are rare neoplasms that present complex challenges to diagnosis and treatment due to their indolent course. The incidence of pancreatic neuroendocrine tumors has increased significantly over the past two decades. A limited number of pancreatic neuroendocrine cell lines are currently available for the research. Here, we present 3D-iNET ORION, a novel 3-dimensional (spheroid) cell line, isolated from human pancreatic neuroendocrine tumor liver metastasis. Three-dimensionally grown (3D) cancer cell lines have gained interest over the past years as 3D cancer cell lines better recapitulate the in vivo structure of tumors, and are more suitable for in vitro and in vivo experiments. 3D-iNET ORION cancer cell line showed high potential to form tumorspheres when embedded in Matrigel matrix and expresses synaptophysin and EpCAM. Electron microscopy analysis of cancer cell line proved the presence of dense neurosecretory granules. When xenografted into athymic mice, 3D-iNET ORION cells produce slow-growing tumors, positive for chromogranin and synaptophysin. Human Core Exome Panel Analysis has shown that 3DiNET ORION cell line retains the genetic aberration profile detected in the original tumor. In conclusion, our newly developed neuroendocrine cancer cell line can be considered as a new research tool for in vitro and in vivo experiments.

Identifiants

pubmed: 39103560
doi: 10.1007/s13577-024-01113-7
pii: 10.1007/s13577-024-01113-7
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Agentúra na Podporu Výskumu a Vývoja
ID : APVV-21-0372
Organisme : NCI NIH HHS
ID : R01 CA256973
Pays : United States
Organisme : NIH (US)
ID : NIH SC1GM121182
Organisme : European Regional Development Fund
ID : ITMS: 313011AFG5

Informations de copyright

© 2024. The Author(s).

Références

Rindi G, Mete O, Uccella S, Basturk O, La Rosa S, Brosens LAA, et al. Overview of the 2022 WHO classification of neuroendocrine neoplasms. Endocr Pathol. 2022;33(1):115–54. https://doi.org/10.1007/s12022-022-09708-2 .
doi: 10.1007/s12022-022-09708-2 pubmed: 35294740
Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a review of neuroendocrine tumors and carcinomas. Neoplasia (New York, NY). 2017;19(12):991–1002. https://doi.org/10.1016/j.neo.2017.09.002 .
doi: 10.1016/j.neo.2017.09.002 pubmed: 29091800
Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine neoplasms of the small bowel and pancreas. Neuroendocrinology. 2020;110(6):444–76. https://doi.org/10.1159/000503721 .
doi: 10.1159/000503721 pubmed: 31557758
Chen M, Van Ness M, Guo Y, Gregg J. Molecular pathology of pancreatic neuroendocrine tumors. J Gastrointest Oncol. 2012;3(3):182–8. https://doi.org/10.3978/j.issn.2078-6891.2012.018 .
doi: 10.3978/j.issn.2078-6891.2012.018 pubmed: 22943010 pmcid: 3418536
Chung C. Management of neuroendocrine tumors. Am J Health-Syst Pharm : AJHP : Off J Am Soc Health-Syst Pharm. 2016;73(21):1729–44. https://doi.org/10.2146/ajhp150373 .
doi: 10.2146/ajhp150373
Hori T, Takaori K, Uemoto S. Pancreatic neuroendocrine tumor accompanied with multiple liver metastases. World J Hepatol. 2014;6(8):596–600. https://doi.org/10.4254/wjh.v6.i8.596 .
doi: 10.4254/wjh.v6.i8.596 pubmed: 25232452 pmcid: 4163742
Jubelin C, Muñoz-Garcia J, Griscom L, Cochonneau D, Ollivier E, Heymann, et al. Three-dimensional in vitro culture models in oncology research. Cell Biosci. 2022;12(1):155. https://doi.org/10.1186/s13578-022-00887-3 .
doi: 10.1186/s13578-022-00887-3 pubmed: 36089610 pmcid: 9465969
Yamasaki AE, Warshaw JN, Kyalwazi BL, Matsui H, Jepsen K, Panopoulos AD. An iPSC line derived from a human acute myeloid leukemia cell line (HL-60-iPSC) retains leukemic abnormalities and displays myeloid differentiation defects. Stem cell research. 2020;49: 102096. https://doi.org/10.1016/j.scr.2020.102096 .
doi: 10.1016/j.scr.2020.102096 pubmed: 33370871 pmcid: 8031422
Grozinsky-Glasberg S, Shimon I, Rubinfeld H. The role of cell lines in the study of neuroendocrine tumors. Neuroendocrinology. 2012;96(3):173–87. https://doi.org/10.1159/000338793 .
doi: 10.1159/000338793 pubmed: 22538498
Ney A, Canciani G, Hsuan JJ, Pereira SP. Modelling pancreatic neuroendocrine cancer: from bench side to clinic. Cancers. 2020;12(11):3170. https://doi.org/10.3390/cancers12113170 .
doi: 10.3390/cancers12113170 pubmed: 33126717 pmcid: 7693644
Edmondson R, Broglie JJ, Adcock AF, Yang L. Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors. Assay Drug Dev Technol. 2014;12(4):207–18. https://doi.org/10.1089/adt.2014.573 .
doi: 10.1089/adt.2014.573 pubmed: 24831787 pmcid: 4026212
Grönholm M, Feodoroff M, Antignani G, Martins B, Hamdan F, Cerullo V. Patient-derived organoids for precision cancer immunotherapy. Can Res. 2021;81(12):3149–55. https://doi.org/10.1158/0008-5472.CAN-20-4026 .
doi: 10.1158/0008-5472.CAN-20-4026
Malosio ML, Giordano T, Laslop A, Meldolesi J. Dense-core granules: a specific hallmark of the neuronal/neurosecretory cell phenotype. J Cell Sci. 2004;117(Pt 5):743–9. https://doi.org/10.1242/jcs.00934 .
doi: 10.1242/jcs.00934 pubmed: 14734658
Fendrich V, Waldmann J, Esni F, Ramaswamy A, Mullendore M, Buchholz M, et al. Snail and sonic hedgehog activation in neuroendocrine tumors of the ileum. Endocr Relat Cancer. 2007;14(3):865–74. https://doi.org/10.1677/ERC-07-0108 .
doi: 10.1677/ERC-07-0108 pubmed: 17914115
Galván JA, Astudillo A, Vallina A, Fonseca PJ, Gómez-Izquierdo L, García-Carbonero R, et al. Epithelial-mesenchymal transition markers in the differential diagnosis of gastroenteropancreatic neuroendocrine tumors. Am J Clin Pathol. 2013;140(1):61–72. https://doi.org/10.1309/AJCPIV40ISTBXRAX .
doi: 10.1309/AJCPIV40ISTBXRAX pubmed: 23765535
Karafin MS, Cummings CT, Fu B, Iacobuzio-Donahue CA. The developmental transcription factor Gata4 is overexpressed in pancreatic ductal adenocarcinoma. Int J Clin Exp Pathol. 2009;3(1):47–55.
pubmed: 19918328
Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for the epithelial-to-mesenchymal transition in pancreatic cancer. Can Res. 2010;70(5):2115–25. https://doi.org/10.1158/0008-5472.CAN-09-2979 .
doi: 10.1158/0008-5472.CAN-09-2979
Eisinger-Mathason TS, Simon MC. HIF-1alpha partners with FoxA2, a neuroendocrine-specific transcription factor, to promote tumorigenesis. Cancer Cell. 2010;18(1):3–4. https://doi.org/10.1016/j.ccr.2010.06.007 .
doi: 10.1016/j.ccr.2010.06.007 pubmed: 20609346 pmcid: 3144028
Park JW, Lee JK, Witte ON, Huang J. FOXA2 is a sensitive and specific marker for small cell neuroendocrine carcinoma of the prostate. Mod Pathol. 2017;30(9):1262–72. https://doi.org/10.1038/modpathol.2017.44 .
doi: 10.1038/modpathol.2017.44 pubmed: 28621319 pmcid: 6330177
Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol : AIMM. 2010;18(1):55–61. https://doi.org/10.1097/PAI.0b013e3181b16b88 .
doi: 10.1097/PAI.0b013e3181b16b88 pubmed: 19661786
Zhu X, Wang X, Gong Y, Deng J. E-cadherin on epithelial-mesenchymal transition in thyroid cancer. Cancer Cell Int. 2021;21(1):695. https://doi.org/10.1186/s12935-021-02344-6 .
doi: 10.1186/s12935-021-02344-6 pubmed: 34930256 pmcid: 8690896
Krieg A, Mersch S, Boeck I, Dizdar L, Weihe E, Hilal Z, et al. New model for gastroenteropancreatic large-cell neuroendocrine carcinoma: establishment of two clinically relevant cell lines. PLoS One. 2014;9(2): e88713. https://doi.org/10.1371/journal.pone.0088713 .
doi: 10.1371/journal.pone.0088713 pubmed: 24551139 pmcid: 3925161
Strnadel J, Woo SM, Choi S, Wang H, Grendar M, Fujimura K. 3D culture protocol for testing gene knockdown efficiency and cell line derivation. Bio Protocol. 2018. https://doi.org/10.21769/BioProtoc.2874 .
doi: 10.21769/BioProtoc.2874 pubmed: 34285988 pmcid: 8275222

Auteurs

Jan Strnadel (J)

Jessenius Faculty of Medicine in Martin, Biomedical Centre Martin, Comenius University in Bratislava, 036 01, Martin, Slovakia. jan.strnadel@uniba.sk.
Department of Pathology, University of California, La Jolla, San Diego, CA, USA. jan.strnadel@uniba.sk.

Mark A Valasek (MA)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.

Grace Y Lin (GY)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.

Huahui Lin (H)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.

Ann M Ponsford Tipps (AMP)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.

Sang Myung Woo (SM)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.
Research Institute, Center for Liver and Pancreatobiliary Cancer, National Cancer Center, Goyang-si, Republic of Korea.

Ken Fujimura (K)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.

Huawei Wang (H)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.

Sunkyu Choi (S)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.
Proteomics Core, Weill Cornell Medicine-Qatar, Qatar Foundation, Education City, Doha, Qatar.

Jack Bui (J)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.
Moores Cancer Center, University of California, La Jolla, San Diego, CA, USA.

Christopher Hermosillo (C)

Institute for Genomic Medicine, University of California, La Jolla, San Diego, CA, USA.

Kristen Jepsen (K)

Institute for Genomic Medicine, University of California, La Jolla, San Diego, CA, USA.

Michael R Navarro (MR)

Neuroregeneration Laboratory, Department of Anesthesiology, University of California San Diego, La Jolla, San Diego, CA, USA.

Jonathan A Kelber (JA)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.
Department of Biology, Baylor University, Waco, TX, USA.

Richard L Klemke (RL)

Department of Pathology, University of California, La Jolla, San Diego, CA, USA.
Moores Cancer Center, University of California, La Jolla, San Diego, CA, USA.

Michael Bouvet (M)

Moores Cancer Center, University of California, La Jolla, San Diego, CA, USA.
Division of Surgical Oncology, Department of Surgery, Moores Cancer Center, University of California San Diego, La Jolla, San Diego, CA, USA.

Classifications MeSH